WILMINGTON, MA--(Marketwire - May 06, 2009) - DUSA Pharmaceuticals, Inc.® (NASDAQ: DUSA) announces that its corporate highlights and first quarter financial results press release will be issued on Tuesday, May 12 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Tuesday, May 12 - 8:30 a.m. E.T.
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA
For International callers use
502.498.8422
A recorded replay of the call will be available approximately 15 minutes
following the call
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site approximately four hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical
company focused primarily on the development and marketing of its
Levulan® photodynamic therapy (PDT) technology platform, and
complementary dermatology products. Levulan® PDT is currently approved
for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp.
DUSA also markets other dermatology products, including ClindaReach®.
DUSA is researching the use of Levulan® PDT to prevent AKs and squamous
cell carcinomas in immunosuppressed solid organ transplant recipients and
is supporting research related to oral leukoplakia in collaboration with
National Institutes of Health (NIH). DUSA is based in Wilmington, Mass.
Please visit our Web site at www.dusapharma.com.
